Elevated levels of the pro-inflammatory signaling protein galectin-3 in the bloodstream of children with clinically stable cystic fibrosis (CF) significantly correlated with worse lung function, according to a study. The findings suggest galectin-3 may serve as a noninvasive biomarker to predict lung disease outcomes in children with CF, the…
News
A history of pancreatic inflammation, diabetes, high blood pressure, and high cholesterol may increase the risk of pancreatic cancer in people with cystic fibrosis (CF), according to a large database report. These patients also had a higher prevalence of known risk factors for pancreatic cancer, including smoking, alcohol consumption,…
People with advanced liver disease associated with cystic fibrosis (CF) have more pro-inflammatory bacteria in their feces relative to those without CF- associated liver disease, a study shows. The findings suggest similar changes in the gut microbiota, or the populations of friendly microbes that naturally live in the intestines. This…
The Cystic Fibrosis Foundation (CFF) has invested another $5 million into BiomX, which will help fund a Phase 2b clinical trial of BX004 — a phage therapy the company is developing to clear up lung infections in cystic fibrosis (CF) caused by the Pseudomonas aeruginosa bacteria. In…
Doctors should take care not to oversimplify when talking to patients about treatment decisions for chronic illnesses, according to patients, caregivers, and physicians interviewed for a study focusing on CFTR modulator therapy for cystic fibrosis (CF). It’s also important to have “compassionate conversations” with patients who aren’t eligible…
The use of the approved medication Trikafta (elexacaftor/tezacaftor/ivacaftor) was shown to significantly increase weight in people with cystic fibrosis-related diabetes (CFRD) and a low body mass index, or BMI, a measure of body fat, in a new study. The researchers say the study’s findings, which also showed…
A protein secreted into the airways, called SPLUNC1, may be a sensitive biomarker of both mild pulmonary exacerbations and treatment response in children with cystic fibrosis (CF), a study suggested. Data showed that SPLUNC1 levels in patients’ sputum were low during an exacerbation, then significantly rose after oral and,…
Gut bacteria called Bacteroides had anti-inflammatory effects in the blood and airways of a mouse model of cystic fibrosis (CF) via its production of an immune-modulating metabolite called propionate, a study finds. The findings add to evidence of a so-called gut-lung axis, where microbes in the gut can influence…
Children with cystic fibrosis (CF) who began taking Orkambi (lumacaftor/ivacaftor) between ages 2 and 5 showed improved height, weight, and body fat content compared with matched patients who hadn’t yet received modulator therapies, a real-world study reports. There was also a 50% decline in the number of pulmonary…
Sotagliflozin, an oral medication approved in the U.S. under the brand name Inpefa as a broadly used treatment for heart failure, may ease symptoms of liver disease related to cystic fibrosis (CF), according to a study in rabbits. While it’s still too early to tell if sotagliflozin will…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.